Department of Internal Medicine, Division of Immunobiology, Saint Louis University, St. Louis, MO 63104, USA.
Infect Immun. 2010 Dec;78(12):5295-306. doi: 10.1128/IAI.00513-10. Epub 2010 Oct 4.
Understanding the regulation of human immune responses is critical for vaccine development and treating infectious diseases. We have previously shown that simultaneous engagement of the T cell receptor (TCR) and complement regulator CD46 on human CD4(+) T cells in the presence of interleukin-2 (IL-2) induces potent secretion of the immunomodulatory cytokine IL-10. These T cells mediate IL-10-dependent suppression of bystander CD4(+) T cells activated in vitro with anti-CD3 and anti-CD28 costimulation, reflecting a T regulatory type 1 (Tr1)-like phenotype. However, CD46-mediated negative regulation of pathogen-specific T cells has not been described. Therefore, we studied the ability of CD46-activated human CD4(+) T cells to suppress T cell responses to Mycobacterium bovis BCG, the live vaccine that provides infants protection against the major human pathogen Mycobacterium tuberculosis. Our results demonstrate that soluble factors secreted by CD46-activated human CD4(+) T cells suppress mycobacterium-specific CD4(+), CD8(+), and γ(9)δ(2) TCR(+) T cells. Dendritic cell functions were not downregulated in our experiments, indicating that CD46-triggered factors directly suppress pathogen-specific T cells. Interestingly, IL-10 appeared to play a less pronounced role in our system, especially in the suppression of γ(9)δ(2) TCR(+) T cells, suggesting the presence of additional undiscovered soluble immunoregulatory factors. Blocking endogenous CD46 signaling 3 days after mycobacterial infection enhanced BCG-specific T cell responses in a subset of volunteers. Taken together, these results indicate that CD46-dependent negative regulatory mechanisms can impair T cell responses vital for immune defense against mycobacteria. Therefore, modulating CD46-induced immune regulation could be integral to the development of improved tuberculosis therapeutics or vaccines.
理解人类免疫反应的调控对于疫苗开发和治疗传染病至关重要。我们之前已经表明,在白细胞介素-2 (IL-2)存在的情况下,同时激活人类 CD4(+) T 细胞上的 T 细胞受体 (TCR) 和补体调节剂 CD46,会诱导免疫调节细胞因子 IL-10 的强烈分泌。这些 T 细胞介导依赖于 IL-10 的抑制作用,抑制体外用抗-CD3 和抗-CD28 共刺激激活的旁观者 CD4(+) T 细胞,反映出 T 调节型 1 (Tr1)样表型。然而,CD46 介导的针对病原体特异性 T 细胞的负调控尚未被描述。因此,我们研究了 CD46 激活的人类 CD4(+) T 细胞抑制针对分枝杆菌牛型结核分枝杆菌 (BCG)的 T 细胞反应的能力,BCG 是一种活疫苗,为婴儿提供针对主要人类病原体结核分枝杆菌的保护。我们的结果表明,CD46 激活的人类 CD4(+) T 细胞分泌的可溶性因子抑制分枝杆菌特异性 CD4(+)、CD8(+)和 γ(9)δ(2)TCR(+)T 细胞。在我们的实验中,树突状细胞功能没有下调,这表明 CD46 触发的因子直接抑制病原体特异性 T 细胞。有趣的是,在我们的系统中,IL-10 似乎发挥的作用不那么明显,特别是在抑制 γ(9)δ(2)TCR(+)T 细胞方面,这表明存在其他未被发现的可溶性免疫调节因子。在分枝杆菌感染后 3 天阻断内源性 CD46 信号,增强了一部分志愿者中 BCG 特异性 T 细胞的反应。综上所述,这些结果表明,CD46 依赖性负调节机制可能损害对分枝杆菌免疫防御至关重要的 T 细胞反应。因此,调节 CD46 诱导的免疫调节可能是开发改良结核病治疗或疫苗的重要组成部分。